Exhibit 99.1

MedAssets Reports Fourth Quarter and Full-Year 2010 Financial Results

ATLANTA--(BUSINESS WIRE)--February 24, 2011--MedAssets, Inc. (NASDAQ: MDAS) today announced results for its fourth quarter and 12-month period ended December 31, 2010, as summarized below:

Net Revenue

Fourth Quarter

Total net revenue for the fourth quarter of 2010 increased 11.8% to $106.9 million from $95.7 million in the fourth quarter of 2009. RCM segment growth of 4.1% was driven by an increase in technology solutions revenue, offset by a decline in services revenue and decision support license fees. Revenue growth of 22.8% in the SM segment was driven by 46 days of revenue from The Broadlane Group (Broadlane), continued strong demand for medical device and clinical consulting services, and growth in group purchasing-related net administrative fees.

Comparing period-over-period organic growth, the Company’s non-GAAP acquisition-affected total net revenue for the fourth quarter of 2010 increased 1.3% to $142.4 million from non-GAAP acquisition-affected total net revenue of $140.5 million in the same period of 2009.

12-month Period

Total net revenue for the year ended December 31, 2010 increased 14.7% to $391.3 million from $341.3 million in 2009.

Comparing period-over-period organic growth, the Company’s non-GAAP acquisition-affected total net revenue for full-year 2010 increased 9.6% to $557.4 million from non-GAAP acquisition-affected total net revenue of $508.8 million in the same period of 2009.

Non-GAAP Adjusted EBITDA

Fourth Quarter

In the fourth quarter of 2010, total non-GAAP adjusted EBITDA was $41.3 million, or 38.6% of total net revenue, a 14.5% increase over total non-GAAP adjusted EBITDA of $36.0 million, or 37.7% of total net revenue, in the fourth quarter of 2009.

Comparing period-over-period organic growth, total acquisition-affected non-GAAP adjusted EBITDA in the fourth quarter of 2010 was $47.5 million, or 33.4% of non-GAAP acquisition-affected total net revenue, a 2.1% decrease from acquisition-affected non-GAAP adjusted EBITDA of $48.6 million, or 34.6% of non-GAAP acquisition-affected total net revenue, in the same period of 2009.

12-month Period

In 2010, total non-GAAP adjusted EBITDA was $128.0 million, or 32.7% of total net revenue, a 14.9% increase over non-GAAP total adjusted EBITDA of $111.4 million, or 32.7% of total net revenue, in 2009.

Comparing period-over-period organic growth, total acquisition-affected non-GAAP adjusted EBITDA in full-year 2010 was $168.7 million, or 30.3% of non-GAAP acquisition-affected total net revenue, a 4.0% increase from acquisition-affected non-GAAP adjusted EBITDA of $162.3 million, or 31.9% of non-GAAP acquisition-affected total net revenue, in 2009.

Net (Loss) Income and Per Share

Fourth Quarter

Net loss in the fourth quarter of 2010 was $49.4 million, or a loss of $0.87 per diluted share, versus net income of $10.0 million, or earnings of $0.17 per diluted share, in the fourth quarter of 2009. The net loss in the fourth quarter of 2010 was due to an impairment charge to write off goodwill associated with the Company’s decision support services (DSS) operating unit, as well as acquisition-related costs and restructuring charges in connection with the acquisition and integration of Broadlane, both of which are described in more detail below.

Non-GAAP cash EPS, defined as EPS excluding non-cash acquisition-related intangible amortization, share-based compensation, acquisition-related expenses and other non-recurring items on a tax-adjusted basis, was $0.18 per diluted share in the fourth quarter of 2010, versus non-GAAP cash EPS of $0.28 per diluted share in the fourth quarter of 2009.

12-month Period

Net loss for the full-year 2010 was $32.1 million, or a loss of $0.57 per diluted share, versus net income of $19.9 million, or earnings of $0.34 per diluted share, in the same period of 2009. Non-GAAP cash EPS was $0.82 per diluted share in 2010, compared to non-GAAP cash EPS of $0.82 per diluted share in 2009.

Cash Flow and Capital Resources

Net cash provided by operating activities in the full-year 2010 increased 75.6% to $105.9 million from $60.3 million in 2009. With new debt financing related to the Broadlane acquisition, MedAssets’ balance sheet at December 31, 2010 included $913.2 million in total bank and bond debt, net of cash and cash equivalents, which represented leverage of approximately 5.4 times trailing 12-month non-GAAP acquisition-affected adjusted EBITDA.

Fourth Quarter 2010 Acquisition-related Adjustments, Costs and Charges

Purchase Accounting Revenue Adjustment - The $13.4 million non-GAAP acquisition-related purchase accounting revenue adjustment reflects net revenue that would have been recognized after completion of the Broadlane acquisition if not for the GAAP-related purchase accounting adjustment. A detailed explanation is provided at the end of this press release under “Use of Non-GAAP Financial Measures.”

Acquisition-related Costs, including Restructuring Charges - The Company incurred $17.2 million in expenses and charges in connection with the acquisition and integration of Broadlane, which were related to the elimination of redundant staff, transaction-related investment banking, audit and legal fees, as well as other costs to achieve targeted synergies. The Company incurred an additional $6.2 million in interest expense related to the write off of unamortized debt issuance costs related to its former credit agreement, the termination of an interest rate swap, and interest expense related to the Broadlane deferred payment.

Business Segment Realignment

Beginning January 1, 2011, the Company’s Spend Management segment was renamed Spend and Clinical Resource Management (SCM) to more accurately reflect the broader clinical resource utilization and performance management capabilities of the organization. Concurrent with the change, the DSS operating unit became part of the SCM segment as a component in the delivery of clinical and financial analytics capabilities.

Impairment Charge

The Company recognized an impairment charge of $44.5 million in the fourth quarter of 2010 to write off goodwill associated with its DSS operating unit given lower than expected expansion of its customer base due to the impact of the economic and competitive environment, as well as capital spending trends by hospitals and health systems.

2011 Financial Guidance

Management introduced the following financial guidance for full-year 2011:

Contracted Revenue Estimates

At December 31, 2010, the Company’s rolling 12-month non-GAAP contracted revenue was an estimated $545.2 million ($211.0 million from the RCM segment and $334.2 million from the SCM segment). This is a year-over-year increase of 55.7% on a consolidated basis, and an 11.3% annual increase excluding contracted revenue added through the Broadlane acquisition.

Non-GAAP contracted revenue estimates from December 31, 2009 to present have been recast to reflect the shift of the DSS operating unit from the RCM segment into the SCM segment, but have not been adjusted for Broadlane prior to December 31, 2010. Refer to the Supplemental Non-GAAP Contracted Revenue Estimates in the financial schedules section for details.

Conference Call Information

The Company intends to file its Form 10-K with the Securities and Exchange Commission on or before March 1, 2011. This filing will contain additional information about the Company’s results of operations.

About MedAssets

MedAssets (NASDAQ: MDAS) partners with healthcare providers to improve their financial strength by implementing revenue cycle, spend and clinical resource management solutions that help capture revenue, control cost, improve margins and cash flow, increase regulatory compliance, and optimize operational efficiency. MedAssets serves more than 180 health systems, 4,000 hospitals and 90,000 non-acute healthcare providers. For more information, go to www.medassets.com.

Use of Non-GAAP Financial Information

In order to provide investors with greater insight, promote transparency and allow for a more comprehensive understanding of the information used by management and the board of directors in their financial and operational decision-making, the Company supplements its consolidated financial statements presented on a GAAP basis with the following non-GAAP financial information: gross fees; gross administrative fees; revenue share obligation; EBITDA; adjusted EBITDA; adjusted EBITDA margin; acquisition-affected net revenue; acquisition-affected EBITDA; acquisition-affected adjusted EBITDA; acquisition-affected adjusted EBITDA margin; acquisition-related purchase accounting revenue adjustment; acquisition-related spend management adjustments; diluted cash EPS; and contracted revenue. Reconciliations of these non-GAAP measures to their most directly comparable GAAP measures, where possible, are included in the accompanying financial schedules. Also, see "Use of Non-GAAP Financial Measures" following the financial schedules for more information.

Safe Harbor Statement

This Press Release contains forward-looking statements within the meaning of the Securities Act of 1933 and the Securities Exchange Act of 1934, as amended by the Private Securities Litigation Reform Act of 1995. Forward-looking statements include the intent, belief or current expectations of the Company and its management team with respect to the Company’s future business operations that include, but are not limited to: 2011 financial guidance, costs and revenue growth, margin and other financial projections; contracted revenue forecasts; and the Company’s ability to successfully integrate and capitalize on synergies associated with the acquisition of Broadlane and any other future acquisitions. Investors are cautioned that any forward-looking statements are not guarantees of future performance, and involve risks and uncertainties, and that actual results may differ materially from those contemplated by such forward-looking statements. Important factors currently known to management that could cause actual results to differ materially from those contemplated by the forward-looking statements in this Press Release include, but are not limited to: failure to realize improvements in performance, efficiency and profitability; failure to complete anticipated sales under negotiations; failure to successfully implement revenue backlog; lack of revenue growth; client losses; and adverse developments with respect to the operation or performance of the Company’s business units or the market price of its common stock. Additional factors that could cause actual results to differ materially from those contemplated within this Press Release can also be found in the Company’s Risk Factor disclosures in its Form 10-K for the year ended December 31, 2009 and its Form 10-Q for the period ended September 30, 2010 filed with the Securities and Exchange Commission and available at http://ir.medassets.com. The Company disclaims any responsibility to update any forward-looking statements.

mdas/F

Use of Non-GAAP Financial Measures

In order to provide investors with greater insight, promote transparency and allow for a more comprehensive understanding of the information used by management and the board of directors in their financial and operational decision-making, the Company supplements its consolidated financial statements presented on a GAAP basis with the following non-GAAP financial information: gross fees; gross administrative fees; revenue share obligation; EBITDA; adjusted EBITDA; adjusted EBITDA margin; acquisition-affected net revenue; acquisition-affected EBITDA; acquisition-affected adjusted EBITDA; acquisition-affected adjusted EBITDA margin; acquisition-related purchase accounting revenue adjustment; acquisition-related SCM adjustments; diluted cash EPS; and contracted revenue.

These non-GAAP financial measures may have limitations as analytical tools and should not be considered in isolation or as a substitute for analysis of the Company’s results as reported under GAAP. The Company compensates for such limitations by relying primarily on the Company’s GAAP results and using non-GAAP financial measures only supplementally. Where possible, the Company provides reconciliations of non-GAAP financial measures to the most directly comparable GAAP measures. Investors are encouraged to carefully review those reconciliations. In addition, because these non-GAAP measures are not measures of financial performance under GAAP and are susceptible to varying calculations, these measures, as defined by the Company, may differ from and may not be comparable to similarly titled measures used by other companies.

Gross fees include gross administrative fees the Company receives pursuant to its vendor contracts and all other fees the Company receives from customers. The Company's revenue share obligation represents the portion of the gross administrative fees the Company is contractually obligated to share with certain of its GPO customers. Net administrative fees (a GAAP measure) are the Company's gross administrative fees net of its revenue share obligation. Total net revenue (a GAAP measure) reflects the Company's gross fees net of its revenue share obligation. These non-GAAP measures assist management and the board of directors and may be helpful to investors in analyzing the Company's growth in its Spend and Clinical Resource Management segment given that administrative fees constitute a material portion of the Company's revenue and are paid to the Company by approximately 1,150 suppliers and other vendors contracted by its GPO, and that the Company's revenue share obligation constitutes a significant outlay to certain of its GPO customers.

The Company defines: EBITDA as net income (loss) before net interest expense, income tax expense (benefit), depreciation and amortization; and adjusted EBITDA as net income (loss) before net interest expense, income tax expense (benefit), depreciation and amortization and other non-recurring, non-cash or non-operating items. EBITDA and adjusted EBITDA are used by the Company to facilitate a comparison of its operating performance on a consistent basis from period to period and provides for a more complete understanding of factors and trends affecting our business. These measures assist management and the board of directors and may be useful to investors in comparing the Company's operating performance consistently over time as it removes the impact of its capital structure (primarily interest charges and amortization of debt issuance costs), asset base (primarily depreciation and amortization) and items outside the control of the management team (taxes), as well as other non-cash (purchase accounting adjustments and imputed rental income) and non-recurring items, from the Company’s operational results. Adjusted EBITDA also removes the impact of non-cash share-based compensation expense and certain acquisition-related charges. EBITDA and adjusted EBITDA are not measures of liquidity under GAAP, or otherwise, and are not alternatives to cash flow from continuing operating activities.

Acquisition-affected results include the activity of Broadlane prior to the Company’s actual ownership. The Broadlane acquisition was consummated on November 16, 2010. These results assume the acquisition of Broadlane occurred on January 1, 2009. Acquisition-affected measures (e.g. acquisition-affected net revenue; acquisition-related SCM adjustments; acquisition-affected EBITDA; acquisition-affected adjusted EBITDA; acquisition-affected adjusted EBITDA margin) are used by management and the board of directors to better understand the extent of growth of the Spend and Clinical Resource Management segment. Given the significant impact that this transaction had on the Company during the fiscal year ended December 31, 2010, the Company believes such acquisition-affected measures may be useful and meaningful to investors in their analysis of such growth. Non-GAAP acquisition-affected measures are for illustrative and informational purposes only and are not intended to represent or be indicative of what the Company's results of operations would have been if this transaction had occurred at the beginning of 2009. These measures also should not be considered representative of the Company's future results of operations.

Acquisition-related purchase accounting revenue adjustment reflects an estimated reduction of net administrative fee revenue. Under the Company’s revenue recognition policies, administrative fees are recorded as revenue when reported to the Company by vendors. GAAP relating to business combinations requires that the Company estimate the amount of customer supply purchases (the driver of administrative fee revenue) occurring prior to the acquisition closing date and to record the fair value of the administrative fees (the asset) to be received from those purchases as an account receivable and any corresponding revenue share obligation as a liability. As vendor reports are received and cash is collected, the Company will not recognize revenue for this acquisition-related purchase accounting revenue adjustment.

The Company defines diluted cash EPS as earnings per share excluding non-cash acquisition-related intangible amortization and non-recurring expense items on a tax-adjusted basis, non-cash tax-adjusted shared-based compensation expense and certain acquisition-related charges on a tax-adjusted basis. Diluted cash EPS is not a measure of liquidity under GAAP, or otherwise, and is not an alternative to cash flow from continuing operating activities. Diluted cash EPS growth is used by the Company as the financial performance metric tied to the vesting of certain equity awards granted pursuant to the Company’s Long-Term Performance Incentive Plan. Use of this measure for this purpose allows management and the board of directors to analyze the Company’s operating performance on a consistent basis by removing the impact of certain non-cash and non-recurring items from our operations, and by rewarding organic growth and accretive business transactions. As a significant portion of senior management’s incentive based compensation is based on the achievement of certain diluted cash EPS growth over time, investors may find such information useful.

Contracted revenue is a forward-looking operating measure used by management and the board of directors to better understand revenue growth trends within the Company's business segments as it reflects the Company’s current estimate of contractually committed revenue to be generated under existing customer contracts in the forward 12-month period. Such information may be useful to investors in their analysis of the Company's revenue growth trends. A reconciliation to the most directly comparable GAAP measure cannot be performed without unreasonable effort.

CONTACT:
MedAssets, Inc.
Robert P. Borchert, 678-248-8194
rborchert@medassets.com